Abstract: A keyboard device is provided with a base plate configured by arranging a plurality of plate members, a plurality of keytops vertically movably supported on the upper surface side of the base plate, a frame attached to the upper surface side of the base plate and having a plurality of hole portions into which the keytops are vertically movably inserted, and a fastening tool provided at a position overlapping with a plate boundary portion formed between the facing end surfaces of the plate members adjacent to each other and simultaneously fastening the adjacent plate members to the frame.

Abstract: A keyboard device is provided with a base plate, a plurality of key tops, a membrane sheet, and a frame. The frame has a frame portion interposed between the key tops adjacent to each other and partitions each key top in a vertically movable state by the formation of a gap between the side surface of the frame portion and the side surface of the key top. The base plate has a notch portion at a position at least overlapping with a portion under the gap.

Abstract: An input device includes a base plate and a push button rotatably provided on a top surface of the base plate. The base plate has a bearing part protruding from the top surface. The push button has an operation surface part receiving a push down operation and a positioning part rotatably supported by the bearing part. The positioning part positions the push button in the plate thickness direction of the bearing part by an abutting part abutting on a first face of the bearing part and a pushing part resiliently biased toward and pushing a second face of the bearing part.

Abstract: Apparatuses and systems that include a keyboard baseplate including a concave structure with a logic substrate housed therein are disclosed. One apparatus includes a keyboard baseplate including a concave structure formed thereon and a lower surface having a side. The apparatus further includes a logic substrate provided on the side of the lower surface of the baseplate and housed within the concave structure. The logic substrate is configured to receive an analog signal generated by a sensor and convert the analog signal to a digital signal.

Abstract: [Problem] Provided is a compound which is useful as an active ingredient of a pharmaceutical composition for treating lung cancer. [Means for Solution] The present inventors have studied a compound useful as an active ingredient of a pharmaceutical composition for treating lung cancer, and as a result, it was found that a quinazoline compound has an excellent G12C mutation KRAS inhibitory activity, and which can be used as a therapeutic agent for lung cancer, and thereby the present invention has been completed. The quinazoline compound of the present invention and a salt thereof may be used as the therapeutic agent for lung cancer.

Abstract: A refrigerant distributor branches refrigerant flowing in a refrigerant circuit into three, and includes a first bifurcate flow divider including a first pipe portion forming one inflow port, a second pipe portion and a third pipe portion forming two outflow ports communicating with the inflow port of the first pipe portion, and a second bifurcate flow divider including a fourth pipe portion forming one inflow port, and a fifth pipe portion and a sixth pipe portion forming two outflow ports communicating with the inflow port of the fourth pipe portion. The outflow port of the third pipe portion and the inflow port of the fourth pipe portion communicate with each other, and an angle ? formed by a first plane passing through the first bifurcate flow divider and a second plane passing through the second bifurcate flow divider is between 60 and 120 degrees.

Abstract: A refrigeration cycle apparatus includes a main circuit through which refrigerant circulates and in which a compressor, a condenser, a first expansion device, a centrifugal gas-liquid separator that separates refrigerant into gas refrigerant and liquid refrigerant by using centrifugal force, and an evaporator are connected by refrigerant pipes; and a bypass that returns the gas refrigerant obtained through the separation by the gas-liquid separator to a suction side of the compressor. The gas-liquid separator includes a cylindrical container, an inflow pipe, a gas outflow pipe, and a liquid outflow pipe. The main circuit includes a second expansion device provided between the liquid outflow pipe of the gas-liquid separator and the evaporator. The gas refrigerant discharged from the gas outflow pipe of the gas-liquid separator flows into the bypass, and the bypass is provided with a third expansion device.

Abstract: A heat exchanger includes a plurality of heat transfer tubes, a first header, a second header, and a plurality of fins. The heat exchanger constitutes a portion of a refrigeration cycle circuit in which refrigerant circulates. The second header includes a header pipe. The header pipe has an entrance portion. A bypass pipe is disposed between the entrance portion and the first header and configured to bypass refrigerant. The bypass pipe protrudes into the header pipe to be connected to the header pipe. The bypass pipe is provided with a flow control mechanism configured to control a flow rate of refrigerant.

Abstract: A heat sink includes a pipe through which cooled fluid flows and a cooling block having a first face on which the pipe is placed and a second face to which a heat emitting element is attached. The cooling block has a contact region and a noncontact region at positions where the cooling block faces the pipe. In the contact region, the first face contacts the pipe. In the noncontact region, the first face faces the pipe with a gap therebetween. The contact region is included in a projection region defined by projecting a region of attachment of the heat emitting element onto the first face.

Abstract: [Problem] Provided is a compound which is useful as an active ingredient of a pharmaceutical composition for treating lung cancer. [Means for Solution] The present inventors have studied a compound useful as an active ingredient of a pharmaceutical composition for treating lung cancer, and as a result, it was found that a quinazoline compound has an excellent G12C mutation KRAS inhibitory activity, and which can be used as a therapeutic agent for lung cancer, and thereby the present invention has been completed. The quinazoline compound of the present invention and a salt thereof may be used as the therapeutic agent for lung cancer.

Abstract: A refrigeration cycle apparatus includes a refrigerant circuit, a controller, a bypass pipe, a refrigerant cooler, a second expansion device, and a controller temperature sensor. In a case where a temperature measured by the controller temperature sensor is lower than or equal to a set temperature in a state where an opening degree of the second expansion device is controlled to an instruction opening degree that is lower than or equal to a set opening degree, the controller is configured to perform foreign substance release control where the controller is configured to increase the opening degree of the second expansion device and then is configured to return the opening degree of the second expansion device to the instruction opening degree.

Abstract: [Problem] Provided is a compound which is useful as an active ingredient of a pharmaceutical composition for treating lung cancer. [Means for Solution] The present inventors have studied a compound useful as an active ingredient of a pharmaceutical composition for treating lung cancer, and as a result, it was found that a quinazoline compound has an excellent G12C mutation KRAS inhibitory activity, and which can be used as a therapeutic agent for lung cancer, and thereby the present invention has been completed. The quinazoline compound of the present invention and a salt thereof may be used as the therapeutic agent for lung cancer.

Abstract: The air-conditioning apparatus includes a heat exchanger including a plurality of heat transfer tubes and a header manifold an axial fan and a refrigerant circuit. When the distance from the center of the flow space in the horizontal plane is represented on a scale of 0 to 100%, where 0% represents the center of the flow space and 100% is the position of the wall surface of the header manifold, among the plurality of branch tubes located within a height range that allows the blade to rotate, the majority of the branch tubes located at or below the height of the boss are connected to the header manifold such that their distal ends are positioned at 0 to 50% of the distance from the center, and the majority of the branch tubes located above the height of the boss are connected to the header manifold such that their distal ends are positioned at more than 50% of the distance from the center.

Abstract: [Problem] Provided is a compound which is useful as an active ingredient of a pharmaceutical composition for treating lung cancer. [Means for Solution] The present inventors have studied a compound useful as an active ingredient of a pharmaceutical composition for treating lung cancer, and as a result, it was found that a quinazoline compound has an excellent G12C mutation KRAS inhibitory activity, and which can be used as a therapeutic agent for lung cancer, and thereby the present invention has been completed. The quinazoline compound of the present invention and a salt thereof may be used as the therapeutic agent for lung cancer.

Abstract: A refrigeration cycle apparatus includes a refrigerant circuit through which refrigerant circulates, a control box in which equipment for controlling the refrigeration cycle apparatus is accommodated, and a refrigerator for cooing a heat emitting body exposed from an opening of the control box. The heat emitting body is the equipment accommodated in the control box. The refrigerator includes a cooling body in contact with the heat emitting body, and a refrigerant pipe through which the refrigerant circulating through the refrigerant circuit passes to cool the cooling body. The refrigerant pipe is in contact with the cooling body. The pipe contact surface is different from the heating-body contact surface. The cooling body has a recessed portion at which the cooling body and the heat emitting body are not in contact with each other. The recessed portion is formed in the heating-body contact surface and spaced from the control box.

Abstract: A header includes a plurality of branch tubes and a header manifold. If refrigerant flowing into the header manifold forms a pattern of annular flow or churn flow, tips of the branch tubes inserted into the header manifold pass through a liquid-phase portion having a thickness ? [m] and reach a gas-phase portion. The thickness ? [m] of the liquid-phase portion is defined as ?=G×(1?x)×D/(4?L×ULS), where G is a flow speed [kg/(m2s)] of the refrigerant, x is a quality of the refrigerant, D is an inside diameter [m] of the header manifold, ?L is a liquid density [kg/m3] of the refrigerant, ULS is a reference apparent liquid speed [m/s] that is a maximum value within a range of variation in an apparent gas speed of the refrigerant flowing into a flow space of the header manifold. The reference apparent liquid speed ULS [m/s] is defined as G(1?x)/?L.

Abstract: A refrigeration cycle apparatus includes a refrigerant circuit, through which refrigerant is circulated, including a compressor, a heat source side heat exchanger, a first expansion device, and a load side heat exchanger, a controller controlling the refrigerant circuit, and a bypass pipe that branches off from a high-pressure pipe extending from the compressor to the first expansion device and that is connected to a low-pressure pipe on a suction side of the compressor. The apparatus further includes a precooling heat exchanger that is provided in the bypass pipe and that cools the refrigerant diverted to the bypass pipe, a second expansion device that is provided in the bypass pipe and that reduces a pressure of the refrigerant cooled by the precooling heat exchanger, and a refrigerant cooler that is provided in the bypass pipe and that cools the controller with the refrigerant reduced in pressure by the second expansion device.

Abstract: [Problem] To provide a compound which is useful as an active ingredient for a pharmaceutical composition for preventing or treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. [Means for Solution] The present inventors have found that a thiazole derivative substituted with pyrazinylcarbonylamino at the 2-position is an excellent muscarinic M3 receptor-positive allosteric modulator and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention. 2-Acylaminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, for example voiding dysfunction such as underactive bladder.

Abstract: [Problem] To provide a compound which is useful as an active ingredient for a pharmaceutical composition for preventing or treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. [Means for Solution] The present inventors have found that a thiazole derivative substituted with pyrazinylcarbonylamino at the 2-position is an excellent muscarinic M3 receptor-positive allosteric modulator and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention. 2-Acylaminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, for example voiding dysfunction such as underactive bladder.

Abstract: Thiazole derivatives having pyrazine-2-carbonylamino substituted at the 2-position of the following formula (I): are excellent muscarinic M3 receptor positive allosteric modulators, and are useful for treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M3 receptor. The 2-acylaminothiazole derivatives and salts thereof can be used for treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M3 receptor, for example, voiding dysfunctions such as underactive bladder.